Advertisement
GKOS vs NTRA
Which Stock Would AI Choose? Glaukos Corporation (GKOS) vs. Natera, Inc. (NTRA) Stock Comparison
Key Takeaways
- Glaukos Corporation (GKOS) reported record Q2 2026 revenue of $185.6 million, reflecting approximately 50% year-over-year growth driven by its ophthalmic product portfolio.
- Natera, Inc. (NTRA) delivered robust long-term returns with one-year gains exceeding 85%, supported by its cell-free DNA (cfDNA) testing platform across oncology and women's health.
- Recent market activity showed (GKOS) shares advancing notably following strong earnings, while (NTRA) experienced volatility ahead of its upcoming Q2 2026 results.
- Both companies operate in the healthcare sector but target distinct therapeutic areas: (GKOS) focuses on eye diseases and (NTRA) on genetic diagnostics.
- Relative performance highlights trade-offs between (GKOS)'s recent revenue momentum and (NTRA)'s established growth trajectory in personalized medicine.
- Market sentiment for both remains influenced by clinical developments and broader biotech sector dynamics in recent weeks.
Introduction
Investors and traders evaluating opportunities in the healthcare sector often compare specialized medical technology and diagnostics companies to assess relative positioning. Glaukos Corporation (GKOS) and Natera, Inc. (NTRA) represent distinct approaches within this space, with one emphasizing ophthalmic therapies and the other advancing cell-free DNA testing. This comparison provides objective insights into business models, recent performance trends, and key differentiators. Market participants seeking to understand sector-specific dynamics, growth catalysts, and risk profiles may find the analysis relevant for portfolio construction or tactical positioning.
GKOS Overview and Recent Performance
Glaukos Corporation develops and commercializes novel therapies for glaucoma, corneal disorders, and retinal diseases. The company focuses on micro-invasive glaucoma surgery devices and sustained-release pharmaceutical platforms. In recent market activity, (GKOS) shares demonstrated notable strength following the release of second-quarter 2026 financial results. Revenue reached a record $185.6 million, increasing nearly 50% year-over-year, supported by expanded adoption of its product offerings. The positive earnings surprise contributed to upward price movement and improved sentiment in recent weeks, building on broader year-to-date gains that have outpaced certain market benchmarks.
NTRA Overview and Recent Performance
Natera, Inc. specializes in cell-free DNA (cfDNA) testing services, serving women's health, oncology, and organ health markets with products such as Panorama and Signatera. The company leverages proprietary molecular and bioinformatics technologies for non-invasive diagnostics. Recent performance for (NTRA) reflected continued long-term appreciation, with one-year returns exceeding 85% amid expanding clinical evidence and test utilization. However, the stock experienced periods of volatility, including reactions to quarterly results and upcoming earnings scheduled for early August 2026. Broader market activity in recent weeks showed resilience tied to oncology and transplant applications.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section on its platform that highlights select AI trading bots optimized for prevailing market conditions. The site features hundreds of AI Trading Bots capable of trading thousands of different tickers, yet only those demonstrating superior suitability, consistency, and adaptability earn placement in this focused section. Available bots encompass a wide range of trading styles, strategies, timeframes, and performance statistics, allowing users to evaluate options aligned with specific objectives. Performance metrics across the platform vary by bot, with historical results spanning different risk levels and market environments. For additional details on these tools, visit the Trending AI Robots page.
Head-to-Head Comparison
Glaukos Corporation (GKOS) and Natera, Inc. (NTRA) operate in different healthcare niches, creating distinct growth drivers and risk exposures. (GKOS) centers on ophthalmic medical devices and pharmaceuticals, benefiting from procedural adoption and regulatory milestones in eye care. In contrast, (NTRA) emphasizes molecular diagnostics, with momentum linked to clinical data expansion and reimbursement trends in oncology and prenatal testing. Recent momentum favored (GKOS) following its strong quarterly revenue beat, while (NTRA) displayed steadier longer-term appreciation alongside nearer-term volatility. Risk factors include regulatory and clinical trial outcomes for both, with (GKOS) more tied to surgical device utilization and (NTRA) to test volume and payer coverage. Sector sentiment in recent weeks reflected broader healthcare innovation themes, underscoring trade-offs between established revenue scale at (GKOS) and high-growth diagnostic potential at (NTRA).
Tickeron AI Verdict
Based on observable factors such as recent revenue consistency, earnings delivery, and relative price stability in the prevailing environment, Tickeron’s AI would currently assign a probabilistic preference toward Glaukos Corporation (GKOS). The company’s demonstrated top-line acceleration and post-earnings response provide measurable support for trend continuation compared with (NTRA)’s more mixed near-term signals ahead of its next report. This assessment remains conditional on ongoing market dynamics and does not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GKOS is a Buy and NTRA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GKOS’s FA Score shows that 1 FA rating(s) are green whileNTRA’s FA Score has 1 green FA rating(s).
- GKOS’s FA Score: 1 green, 4 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GKOS’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- GKOS’s TA Score: 4 bullish, 4 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
GKOS (@Medical/Nursing Services) experienced а +9.19% price change this week, while NTRA (@Medical Specialties) price change was +15.07% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.68%. For the same industry, the average monthly price growth was +2.59%, and the average quarterly price growth was -5.03%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.62%. For the same industry, the average monthly price growth was +7.93%, and the average quarterly price growth was +24.12%.
Reported Earning Dates
GKOS is expected to report earnings on Nov 04, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.68% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.62% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| GKOS | NTRA | GKOS / NTRA | |
| Capitalization | 11.2B | 44.8B | 25% |
| EBITDA | -141.49M | -227.7M | 62% |
| Gain YTD | 65.291 | 37.920 | 172% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 613M | 2.5B | 25% |
| Total Cash | 286M | 1.09B | 26% |
| Total Debt | 103M | 240M | 43% |
GKOS | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 33 | 22 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 36 | 36 | |
P/E GROWTH RATING 1..100 | 57 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (49) in the Biotechnology industry is somewhat better than the same rating for GKOS (95) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than GKOS’s over the last 12 months.
NTRA's Profit vs Risk Rating (22) in the Biotechnology industry is in the same range as GKOS (33) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to GKOS’s over the last 12 months.
NTRA's SMR Rating (96) in the Biotechnology industry is in the same range as GKOS (98) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to GKOS’s over the last 12 months.
NTRA's Price Growth Rating (36) in the Biotechnology industry is in the same range as GKOS (36) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to GKOS’s over the last 12 months.
GKOS's P/E Growth Rating (57) in the Medical Specialties industry is somewhat better than the same rating for NTRA (100) in the Biotechnology industry. This means that GKOS’s stock grew somewhat faster than NTRA’s over the last 12 months.
| GKOS | NTRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 78% | 10 days ago 80% |
| Declines ODDS (%) | 17 days ago 68% | 3 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 80% |
Advertisement
GKOS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GKOS has been loosely correlated with ISRG. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GKOS jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To GKOS | 1D Price Change % | ||
|---|---|---|---|---|
| GKOS | 100% | +2.54% | ||
| ISRG - GKOS | 51% Loosely correlated | +0.01% | ||
| NTRA - GKOS | 48% Loosely correlated | +1.04% | ||
| RDNT - GKOS | 48% Loosely correlated | +0.80% | ||
| TWST - GKOS | 46% Loosely correlated | +1.70% | ||
| ALGN - GKOS | 43% Loosely correlated | +0.61% | ||
More | ||||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +1.04% | ||
| ISRG - NTRA | 53% Loosely correlated | +0.01% | ||
| GH - NTRA | 50% Loosely correlated | +0.01% | ||
| ADPT - NTRA | 50% Loosely correlated | -0.55% | ||
| MTD - NTRA | 47% Loosely correlated | +0.09% | ||
| GKOS - NTRA | 47% Loosely correlated | +2.54% | ||
More | ||||